Date: January 29, 2019 at 10AM ET (7AM PT)
Please join FortéBio and Abveris for an exclusive webinar featuring Colby Souders, Chief Scientific Officer of Abveris, who will review ways to utilize Octet screening to streamline antibody discovery projects.
Who should attend:
- Antibody discovery scientists and researchers engaged in therapeutic drug discovery.
- Anyone interested in learning more about leveraging high-throughput Octet screening analyses to advance research and development.
Integrating Octet into Early Antibody Discovery Workflows
Colby Souders, Chief Scientific Officer, Abveris
As industry-wide advancements in antibody drug discovery continue to push toward larger panels of candidates for early-stage characterization, more efficient identification of lead molecules through enhanced screening resolution is required. Integrating instruments like the Octet into the overall characterization workflow enables reliable, high throughput selection of lead candidates more effectively than alternative traditional techniques. This presentation will highlight a few unique methods of Octet utilization as a replacement or supplemental tool for various antibody discovery protocols. Comparisons across platforms, including traditional ELISA, flow cytometry, SPR, and in vivo studies will be presented.